The FDA announced on 2013-03-18 that Boehringer Ingelheim Roxane Inc voluntarily recalled Oxcarbazepine Tablets, 150 mg, due to potential subpotency issues. The agency stated the firm discovered out-of-specification assay results and a potential for lower weight tablets.
How to tell if you have it
- Brand: Roxane Laboratories
- Product: Oxcarbazepine Tablets 150 mg
- NDC 0054-0097-20: 10 x 10 count Unit-Dose Tablets in blisters packaged in a carton
- NDC 0054-0097-25: 100-count bottle
- Lot #: 259666A, Exp. MAR 2014
- Lot #: 259666B, Exp. MAR 2014
The hazard
The hazard is a subpotent drug risk. The firm discovered out of specification results for assay and the extended investigation revealed the potential for lower weight tablets.
Context
GovInfoNow's records show Boehringer Ingelheim Roxane Inc has 12 other recalls on record since 2012-11-05. Other recent recalls of similar products include FUROSEMIDE Tablets USP Recall (2015-09-25), Acarbose 50mg Tablets Recall (2015-04-02), busPIRone 5mg Tablets Recall (2026-04-13), Paxil CR 37.5mg Tablets Recall (2026-08-13), and Levothyroxine Tablets Recall (2026-07-13).